Sigilon Therapeutics Stock Total Asset
| SGTXDelisted Stock | USD 21.11 0.33 1.54% |
Sigilon Therapeutics fundamentals help investors to digest information that contributes to Sigilon Therapeutics' financial success or failures. It also enables traders to predict the movement of Sigilon Stock. The fundamental analysis module provides a way to measure Sigilon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sigilon Therapeutics stock.
Sigilon |
Sigilon Therapeutics Company Total Asset Analysis
Sigilon Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Sigilon Therapeutics Total Asset | 87.28 M |
Most of Sigilon Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sigilon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Sigilon Therapeutics has a Total Asset of 87.28 M. This is 98.84% lower than that of the Biotechnology sector and 95.58% lower than that of the Health Care industry. The total asset for all United States stocks is 99.7% higher than that of the company.
Sigilon Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sigilon Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sigilon Therapeutics could also be used in its relative valuation, which is a method of valuing Sigilon Therapeutics by comparing valuation metrics of similar companies.Sigilon Therapeutics is currently under evaluation in total asset category among its peers.
Sigilon Fundamentals
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (1.71) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 28.99 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 8.69 % | |||
| Shares Owned By Institutions | 54.33 % | |||
| Number Of Shares Shorted | 8.23 K | |||
| Price To Book | 0.25 X | |||
| Price To Sales | 0.87 X | |||
| Revenue | 12.94 M | |||
| Gross Profit | (24.69 M) | |||
| EBITDA | (41.27 M) | |||
| Net Income | (43.56 M) | |||
| Cash And Equivalents | 88.21 M | |||
| Cash Per Share | 2.72 X | |||
| Total Debt | 28.06 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 2.77 X | |||
| Book Value Per Share | 10.97 X | |||
| Cash Flow From Operations | (51.47 M) | |||
| Short Ratio | 0.11 X | |||
| Earnings Per Share | (14.83) X | |||
| Target Price | 47.33 | |||
| Number Of Employees | 62 | |||
| Beta | 4.12 | |||
| Market Capitalization | 56.22 M | |||
| Total Asset | 87.28 M | |||
| Retained Earnings | (256.8 M) | |||
| Working Capital | 43.42 M | |||
| Z Score | -3.73 | |||
| Net Asset | 87.28 M |
About Sigilon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sigilon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sigilon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sigilon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |